Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis

Arthritis Rheum. 1993 Oct;36(10):1375-9. doi: 10.1002/art.1780361008.


Objective: To investigate the effects of chimeric CD4 monoclonal antibody cM-T412 treatment in patients with rheumatoid arthritis (RA).

Methods: Thirty-two RA patients received daily doses of 10, 50, or 100 mg of cM-T412 intravenously for 7 days.

Results: There was a sustained decrease in the number of CD4+ T lymphocytes in all patients. Those who received 50 mg and 100 mg of the antibody experienced significant reductions in disease activity.

Conclusion: Treatment with cM-T412 appears to have a dose-dependent beneficial effect in RA patients. The clinical effects of cM-T412 are independent of the depressed numbers of circulating CD4+ T cells.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use*
  • Arthritis, Rheumatoid / physiopathology
  • Arthritis, Rheumatoid / therapy*
  • CD4 Antigens / immunology*
  • Female
  • Humans
  • Immunotherapy
  • Male
  • Middle Aged
  • Recombinant Fusion Proteins / therapeutic use
  • Severity of Illness Index


  • Antibodies, Monoclonal
  • CD4 Antigens
  • Recombinant Fusion Proteins